Navigation Links
Sanaria's PfSPZ Vaccine Confers Significant Protection Against Natural Malaria infections in Mali
Date:2/15/2017

BETHESDA, Md., Feb. 15, 2017 /PRNewswire/ -- In a report published today in The Lancet Infectious Diseases, (Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed Malian adults: a randomised, double-blind trial) investigators reported that Sanaria® PfSPZ Vaccine protected against natural infections of Plasmodium falciparum, the leading cause of malaria deaths and that protection was sustained for the 24 weeks of the study in an area of intense malaria transmission. 

The study was conducted in Donéguébougou, Mali and was led by Dr. Mahamadou Sissoko of the Malaria Research and Training Center at the University of Science, Techniques and Technologies of Bamako, Mali and by Dr. Sara Healy of the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health in Bethesda, Maryland.

In the Mali study, five doses of PfSPZ Vaccine were administered to 44 subjects and saltwater placebo was given to 44 subjects. Volunteers were followed for six months through the subsequent rainy season to determine the presence of malaria parasites in the blood.  While a staggering 93% of the placebo group had one or more infections, only 66% of the vaccinated subjects acquired an infection and in those vaccinated subjects who became infected, the time to infection was delayed.  This represents 48% protective efficacy by time-to-event analysis and 29% efficacy by proportional analysis.  There were no differences in adverse events between the vaccinated group and the placebo group.

Sanaria CEO, Stephen L. Hoffman, MD said, "These are extremely encouraging results as we have seen significant protection with a dosage regimen that we know to be sub-optimal.  We are now building on the protective efficacy seen in this first, landmark study of efficacy of PfSPZ Vaccine in Africa in current clinical trials of PfSPZ Vaccine underway in Tanzania, Equatorial Guinea, Burkina Faso, Germany, the U.S., and of course in Mali.  We feel that we are moving rapidly toward establishing a dosage regimen that will provide the high level protection needed by the billions of people at risk every day from this lethal disease."

PfSPZ Vaccine is composed of live, radiation-attenuated purified, cryopreserved malaria parasites, which are administered in a 0.5 mL injection rapid direct venous inoculation.

African children are hardest hit by malaria. The World Health Organization estimates that in 2015 malaria caused 214M clinical episodes and 438,000 deaths worldwide; others have estimated up to 730,500 malaria deaths in 2015. This enormous morbidity and mortality occurs despite investment of billions of dollars in malaria control efforts. Malaria is also a concern for tourists, diplomats, business travelers, aid workers, industrial workers, and military personnel worldwide.

Professor Ogobara Doumbo, MD, PhD, Director of the Malaria Research Training Center at the University of Bamako, Mali, said, "Many of us living in countries where people's lives are devastated by malaria have been waiting decades for a highly effective malaria vaccine. Over the past decade we have studied many experimental malaria vaccines in Mali. This is by far the best result we have ever obtained. We are excited and encouraged by these new results, and are proud to have hosted the first field efficacy trial of PfSPZ Vaccine in Africa here in Mali, and are expectantly awaiting the results of our second study."

"These important results provide the evidence that protection against infection, not just disease, can be sustained for at least half a year.  This is clearly a cornerstone for us to finally hone in on a PfSPZ Vaccine regimen that will provide high level, lasting protection to people living in malaria affected areas," said Professor Marcel Tanner, President of the Swiss Academy of Sciences and Director Emeritus, Swiss Tropical and Public Health Institute. "Such a vaccine is an essential tool to achieve elimination.  We are excited about current and all planned future clinical trials of PfSPZ Vaccine that now stretch across Africa from Tanzania in the East to Equatorial Guinea in the West."

About Sanaria Inc.: Sanaria's mission is to commercialize whole-parasite malaria vaccines that confer high level, long-lasting protection against malaria, and use these vaccines to prevent malaria in individuals and eliminate malaria from entire regions.  Sanaria (http://www.sanaria.com) is based in Rockville, Maryland.

This news release contains certain forward-looking statements that involve known and unknown risks and uncertainties, which may cause actual results to differ materially from anticipated results or achievements expressed or implied by the statements made. Such statements include the availability of an effective vaccine, the expectations for eliminating malaria, and beliefs concerning the suitability of a successful vaccine. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the Company's ability to raise sufficient funds, the regulatory approval process, clinical trials results, the Company's patent portfolio, dependence on key personnel and other risks associated with vaccine development. For further information contact Alexander Hoffman, press@sanaria.com, 301-339-0092.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sanarias-pfspz-vaccine-confers-significant-protection-against-natural-malaria-infections-in-mali-300407838.html


'/>"/>
SOURCE Sanaria Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. PfSPZ-CVac-Malariaimpfstoff von Sanaria erzielt in klinischer Studie hohen Schutzgrad
2. Expanded Vaccine offering for PharmaJet Needle-free Device
3. Addario Lung Cancer Medical Institute and Scancell Holdings PLC Form Partnership to Advance Lung Cancer Vaccine Clinical Trials
4. Immunomodulators Market Analysis By Product (Immunosuppressant, Immunostimulants, Vaccines, Antibodies), By Application (Oncology, Respiratory, HIV), By Region, And Segment Forecasts, 2014 - 2025
5. Global Influenza Vaccines - World Industry Market Outlook 2017-2027
6. Global Lung Cancer Vaccine Market & Pipeline Outlook 2022
7. Porcine Vaccine Market, and Porcine Circovirus Associated Disease; End User - North America Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
8. CSRAs DynPort Vaccine Company to Help Advance Medical Products for the National Institute of Allergy and Infectious Diseases
9. BioNet Received Thai FDA Approval of the Worlds Only Available Recombinant Monovalent Acellular Pertussis (aP) Vaccine
10. Research Firm Notes "Top Five Vaccine Industry Trends" of 2016
11. Global Cancer Vaccine Market & Clinical Trial Insight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... Sept. 8, 2017 Dealmed Medical Supplies, ... of medical equipment, supplies, drugs, vaccines, and specialty medical ... into an agreement to acquire Vantage Medical Supplies, a ... Holtsville, New York . ... new and emerging medical practices, will operate under the ...
(Date:9/7/2017)... , Sept. 7, 2017  Eli Lilly ... announced actions to streamline operations to more efficiently ... improve its cost structure. Global workforce reductions, including ... are expected to impact approximately 3,500 positions. ... company expects annualized savings of approximately $500 million ...
(Date:9/7/2017)... Texas , Sept. 7, 2017 ... science focused on fulfilling the promise of precision ... further validate the benefits of its molecular profiling ... study utilized comprehensive genomic profiling plus (CGP+) with ... individual patient,s tumor on a molecular level, leading ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... “The Financial Favor of God; Second Edition”: a ... Second Edition” is the creation of published author, Brooks Rathell. , “We typically hear ... to you about the financial favor of God. Not only does it exist, but ...
(Date:9/19/2017)... , ... September 19, 2017 , ... Only a few ... honorees include Brevard’s own Ross A. Clevens, MD, FACS . The founder and ... Facial Plastic and Reconstructive Surgeon who trained at Yale, Harvard and the University of ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... for the President’s Malaria Initiative (PMI) Africa Indoor Residual Spraying (AIRS) Project ... Award. , The Innovation to Action Award, a USAID Catalyst Award, recognizes ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... addition of Canyon Ranch to its recently formed Corporate Roundtable, a ... sustainable healthcare system and a sustainable world. , Canyon Ranch is a unique ...
(Date:9/19/2017)... FORT LEE, N.J. (PRWEB) , ... September 19, 2017 , ... ... of the Subperiosteal Implant: Volume II ” (published by Xlibris on July of 2014). ... and reviews conventional and new methodological approaches that benefit people who have lost ...
Breaking Medicine News(10 mins):